The High Court ruling upholding the National Institute for Health and Clinical Excellence's decision over medication for Alzheimer's is just the latest skirmish in what promises to be protracted manoeuvring over drug use and pricing.
With a HSJ subscription you’ll unlock:
Already a subscriber? Sign into your account here